Hyperbolic inhibition: our unique mechanism of action
Remedy Plan’s novel hyperbolic inhibitors partially decrease an enzyme’s activity instead of shutting it down entirely. This enables us to target essential enzymes, like NAMPT, without toxicity to normal cells.
Hyperbolic inhibition: our unique mechanism of action
Remedy Plan’s novel hyperbolic inhibitors partially decrease an enzyme’s activity instead of shutting it down entirely. This enables us to target essential enzymes, like NAMPT, without toxicity to normal cells.
Hyperbolic inhibition: our unique mechanism of action
Remedy Plan’s novel hyperbolic inhibitors partially decrease an enzyme’s activity instead of shutting it down entirely. This enables us to target essential enzymes, like NAMPT, without toxicity to normal cells.
Hyperbolic inhibition:
our unique mechanism
of action
Remedy Plan’s novel hyperbolic inhibitors partially decrease an enzyme’s activity instead of shutting it down entirely. This enables us to target essential enzymes, like NAMPT, without toxicity to normal cells.
Hyperbolic inhibition:
our unique mechanism
of action
Remedy Plan’s novel hyperbolic inhibitors partially decrease an enzyme’s activity instead of shutting it down entirely. This enables us to target essential enzymes, like NAMPT, without toxicity to normal cells.
Hyperbolic inhibition: our unique mechanism of action
Hyperbolic inhibition:
our unique mechanism
of action
Remedy Plan’s novel hyperbolic inhibitors partially decrease an enzyme’s activity instead of shutting it down entirely. This enables us to target essential enzymes, like NAMPT, without toxicity to normal cells.
Hyperbolic inhibition: our unique mechanism of action
Remedy Plan’s novel hyperbolic inhibitors partially decrease an enzyme’s activity instead of shutting it down entirely. This enables us to target essential enzymes, like NAMPT, without toxicity to normal cells.
Hyperbolic inhibition: our unique mechanism of action
Remedy Plan’s novel hyperbolic inhibitors partially decrease an enzyme’s activity instead of shutting it down entirely. This enables us to target essential enzymes, like NAMPT, without toxicity to normal cells.
Hyperbolic
inhibition:
our unique mechanism
of action
How hyperbolic inhibition works to kill cancer cells
Cancer cells need a lot of energy and require large amounts of NAD to fuel their uncontrolled growth. To support this demand, cancer cells become highly dependent on NAMPT activity.
When we use RPT1G, our hyperbolic inhibitor, to turn down NAMPT activity, cancer cells cannot produce the energy they require and the cells die. In contrast, healthy cells still have enough NAMPT activity to support their energy needs.
Clinically, this means you can treat diseases caused by NAMPT dysregulation without the on-target toxicities seen with previous approaches.
How hyperbolic inhibition works to kill cancer cells
Cancer cells need a lot of energy and require large amounts of NAD to fuel their uncontrolled growth. To support this demand, cancer cells become highly dependent on NAMPT activity.
When we use RPT1G, our hyperbolic inhibitor, to turn down NAMPT activity, cancer cells cannot produce the energy they require and the cells die. In contrast, healthy cells still have enough NAMPT activity to support their energy needs.
Clinically, this means you can treat diseases caused by NAMPT dysregulation without the on-target toxicities seen with previous approaches.
Mechanism of Action
RPT1G: the first
well-tolerated NAMPT inhibitor
Remedy Plan’s lead asset is RPT1G, a clinical drug candidate for the treatment of solid and hematologic malignancies.
RPT1G is the first well-tolerated NAMPT inhibitor, shown to be safe in humans. In a healthy volunteer Phase 1 clinical trial (NCT#06667765), RPT1G was safe and well-tolerated at single and multiple ascending dose levels, with no reports of Grade > 2 treatment emergent adverse events (TEAE), serious adverse events, or TEAE leading to drug discontinuation in any cohort.
Target engagement data indicate that RPT1G inhibits NAMPT in humans at doses predicted to be clinically meaningful for the treatment of hematologic malignancies.
